University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Qingsheng Li Publications

Papers in the Biological Sciences

2010

Challenges and counter challenges in HIV/AIDS
Qingsheng Li
University of Nebraska-Lincoln, qli4@unl.edu

Charles Wood
University of Nebraska-Lincoln, cwood1@unl.edu

Follow this and additional works at: http://digitalcommons.unl.edu/biosciqingshengli
Li, Qingsheng and Wood, Charles, "Challenges and counter challenges in HIV/AIDS" (2010). Qingsheng Li Publications. 10.
http://digitalcommons.unl.edu/biosciqingshengli/10

This Article is brought to you for free and open access by the Papers in the Biological Sciences at DigitalCommons@University of Nebraska - Lincoln.
It has been accepted for inclusion in Qingsheng Li Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

3379

Chinese Medical Journal 2010;123(23):3379-3380

Editorial
Challenges and counter challenges in HIV/AIDS
Qingsheng Li and Charles Wood

S

ince the beginning of the HIV/AIDS pandemic, there
has been significant progress in combating the virus.
In addition to identifying HIV,1 scientists have developed
an array of antiretroviral drugs and successfully
converted the once deadly disease into a treatable and
chronic condition.2 Nevertheless, this battle is far from
over and HIV still outsmarts humans in multiple ways
and poses tremendous challenges. Within this context, the
Chinese Medical Journal has timely published this
special issue on HIV/AIDS, highlighting the ongoing
challenges posed by HIV and potential solutions to these
problems.
The most daunting challenge is to develop prophylactic
measures such as vaccines and microbicides to prevent
HIV transmission. HIV vaccine development has been
dominated by a theme of frustration and failure, best
exemplified by the futility of the Merck Ad5 phase IIb
T-cell vaccine.3 Recently for the first time in the history
of HIV vaccine efficacy trials, human RV144 Thai trial
revealed a modest but significant improvement in efficacy
against HIV transmission.4 However, researchers still
have yet to identify the immune correlates of
RV144-vaccine-induced-protection or to find the best
way to design HIV vaccine post-RV144 to enhance
modest protection to a level that is practical for clinical
use. Recent reconstruction of an exceptionally broadly
neutralizing antibody-VRC015,6 using novel approaches
may open a new avenue for better understanding and
design of immunogenic antigen to elicit broadly
neutralizing antibodies through vaccination.
Dr. Wan and colleagues7 on page 3489 of this issue
reviewed the current state of HIV-1 vaccine development
encompassing the present understanding of the basic
biology of newly transmitted virus, tailoring innate
immune response through toll-like receptors and dendritic
cells to elicit protective adaptive immunity, especially at
the mucosal site of viral entry. Of note, this review also
covered the important issues of immunogenicity, new
adjuvants and replication competent vectors, and the state
of AIDS vaccine clinical trials in China.
Similar to the difficulties in developing an HIV vaccine,
HIV microbicides have also faced numerous unsuccessful
efficacy trials except for the recent CAPRISA 004 trial.
The 004 trial demonstrated a reduction of HIV acquisition
by an estimated 39% overall and by 54% in women with
high gel adherence using 1% vaginal gel formulation of
tenofovir, a nucleotide reverse transcriptase inhibitor.8
Many of topical microbicide candidates advanced into

clinical trials have failed, such as nonooxynol-9, because
they can cause mucosal inflammation and damage.9 Thus
identification of mucosal inflammatory biomarkers to
evaluate the mucosal toxicity of candidate microbicides is
urgently needed. Dr. Li and his colleagues10 on page 3381
assessed the cytokine profiles in mouse vaginal secretion
and histopathological changes in cervicovaginal mucosa
after vaginal exposure to Nonooxynol-9. They found that
interleukin-17A (IL-17A), IL-6, IL-4 and IL-10 are
significantly correlated with mucosal damage caused by
nonooxynol-9. This study indicates that profiling of
cytokines in vaginal secretion may be a useful tool to
predict the mucosal toxicity induced by candidate
microbicides.
Some other challenges in the HIV/AIDS research field
are treatment related, such as drug resistance,
complications associated with anti-retroviral therapy
(ART), and treatment management in persons with
opportunistic infections or other pathogen coinfection.
HIV drug resistance can be acquired through transmission
and/or post transmission during ART, jeopardizing the
success of ART. Detecting and monitoring of
drug-resistant virus is of importance for treatment
management at individual and population levels.11 Since
developing countries use different and limited ART drugs
from developed countries, drug resistance data from
foreign registries are not directly applicable.
Dr. Guo and his colleagues12 on page 3389 reported the
detection of the most common non-nucleoside reverse
transcriptase inhibitor (NNRTI) or nucleoside reverse
transcriptase inhibitor (NRTI) drug resistant mutations in
Chinese HIV+ individuals using allele-specific real-time
PCR and found this method to be much more sensitive
than bulk sequencing. This method can now be used to
monitor drug resistance in HIV infected individuals in
China.
Dr. Zeng and his colleagues13 on page 3396 in this issue
measured arterial stiffness using pulse wave velocity
(PWV) analyses in Chinese HIV+ individuals. They found
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that HIV+ individuals not receiving ART have
significantly higher PWV than that of HIV− individuals,
indicating that HIV infection may increase arterial wall
stiffness; HIV+ individuals receiving ART (only NNRTI
or NRTI) have significantly lower PWV than that of HIV+
individuals not receiving ART.
Dr. Zhang and his colleagues14 on page 3400 conducted a
retrospective cross-sectional study on pulmonary
tuberculosis in HIV+ individuals and found that 4.4% of
Chinese HIV+ individuals (CD+ <350 cells/µl) were
coinfected with pulmonary tuberculosis.
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While the conclusions of the above three studies need to
be validated in a more powered and longitudinal studies,
the results of these studies are informative.
10.

HIV R144 vaccine trial provides us optimism for
countering the challenges posed by HIV/AIDS;
nonetheless there is still a long fight ahead against this
versatile virus. This special issue on HIV/AIDS is just
another step of this long journey to the ultimate defeat of
HIV.
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